|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.9 ILa | -2.20% |
|
-5.32% | +154.29% |
| Apr. 29 | Top Premarket Gainers | MT |
| Mar. 20 | Top Midday Gainers | MT |
XTL Biopharmaceuticals Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported net loss was USD 1.5 million compared to USD 0.6 million a year ago. Basic loss per share from continuing operations was USD 0.003 compared to USD 0.001 a year ago.
Diluted loss per share from continuing operations was USD 0.003 compared to USD 0.001 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +154.29% | 13.2M | |
| +1.77% | 42.86B | |
| +45.32% | 41.36B | |
| +12.24% | 42.74B | |
| -8.83% | 27.68B | |
| +7.44% | 25.15B | |
| -23.01% | 18.63B | |
| +30.56% | 12.37B | |
| -1.82% | 11.92B | |
| +8.35% | 11.21B |
XTL BIOPHARMACEUTICALS LTD. 
